Bio-Thera

Bio-Thera Solutions, Ltd. (Bio-Thera) is a science-driven global biopharmaceutical company based in Guangzhou, China. Adhering to the philosophy of "Innovation for Life," the company leverages discoveries from modern bioscience research to develop a new generation of innovative drugs and biosimilars for the treatment of cancer, autoimmune diseases, cardiovascular diseases, ophthalmic conditions, and other serious diseases that threaten human life or health. The company officially listed on the STAR Market of the Shanghai Stock Exchange in February 2020, with the stock code 688177. As a leader in the development of next-generation antibody drugs, Bio-Thera has advanced multiple drug candidates into late-stage clinical trials. Among them, Golimumab® (Adalimumab), Pubeihi® (Bevacizumab), and Shiruili® (Tocilizumab) have been approved for marketing in China. Tocilizumab (BAT1806) (US brand name: TOFIDENCE™) and Bevacizumab (BAT1706) (US brand name: Avzivi®) have received approval in the United States. The company has over 20 different products in clinical stages, primarily focusing on post-PD-1 era immuno-oncology therapies and antibody-drug conjugates (ADCs) in the field of oncology. The company consistently prioritizes patient welfare as its core value, providing safe, effective, and affordable high-quality medicines through innovative R&D to address unmet medical needs.